About us

ANTABIO is a private biopharmaceutical company developing the next generation of antibiotic resistance breakers in areas of highest unmet medical needs. We are developing stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. Our lead product is expected to enter the clinic in 2019 with fast track to potential marketing approval by 2021.


Nosocomial infections



Bandeau Région FEDER